Astellas Pharma Inc. (ALPMY)
Develops and sells medicines for cancer, eye disease, bladder problems, and other conditions.
$13.64+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+29.0%
The outlook
ALPMY is trading near the middle of its 52-week range with a neutral analyst lean. The average price target sits about 28% above the current price, though the stock shows mixed momentum against its moving averages. A trailing P/E of 13.5 suggests moderate valuation relative to earnings.
What’s behind the score
Price trendMixed vs its moving averages
52-week range50% of the way from its 52-week low to high
Price targetAvg target +28% vs current price
Market cap
$24.44B
52-wk high
$17.35
52-wk low
$9.99
50-day avg
$13.52
200-day avg
$13.84
Trailing P/E
13.5